Identification
Instrument name
IMMUPHARMA
Symbol
ALIMM
ISIN code
GB0033711010
LEI code
213800VZKGHXC7VUS895
Exchange / Market
Euronext Growth
Trading location
Brussels
Products family
Stocks
ICB
Biotechnology
Website address
Operation
IPO date
Issue type
Direct listing

Company profile

ImmuPharma plc specializes in the research and development of therapeutic products focused on peptide technology for the treatment of autoimmune diseases, cancers, ophthalmological diseases and metabolic disorders. At the end of 2018, the portfolio had two products in clinical development (Lupuzor for the treatment of lupus and Nucant for the treatment of cancer) and Urelix, a peptide technology platform through a collaboration with the CNRS targeting notably the treatment of diabetes. ImmuPharma PLC is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG).

Source: ImmuPharma plc - Last Update: 12 Mar 2020
Key Executives
Chief Executive Officer Dimitri Dimitriou
Company Secretary Tracy Weimar
Chief Financial Officer Tracy Weimar
VP, Investor Relations Lisa Baderoon
Source: Cofisem - Last Update: 17 Dec 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales 89 166 183 84 205
Income from ordinary activities 89 166 183 84 205
Operating income -8,972 -8,033 -7,316 -5,067 -3,803
Cost (net) of financial indebtedness 7 -3 11 65
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -8,003 -6,910 -5,912 -4,327 -3,188
Net income (Group share) -8,003 -6,910 -5,912 -4,327 -3,188
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 20 Mar 2020
Shareholder information
Robert Zimmer 15.14 %
Lanstead Capital Investors LP 13.86 %
Source: Cofisem - Last Update: 17 Dec 2019